Literature DB >> 21708057

Nebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study.

Sally E Wenzel1, Cynthia B Robinson, Joanne M Leonard, Reynold A Panettieri.   

Abstract

Inhaled dehydroepiandrosterone-3-sulfate (DHEAS), but not dehydroepiandrosterone (DHEA), possesses anti-inflammatory activity in in vitro assays and in models of allergen and lipopolysaccharide challenges. We postulated whether an inhaled suspension of DHEAS delivered via nebulizer would improve asthma control in moderate-to-severe asthma patients. We also characterized the safety profile of an inhaled suspension of DHEAS. Patients receiving at least 500 μg of fluticasone equivalent plus long-acting beta-agonists (LABA) entered a 5-week run-in where the dose of inhaled corticosteroids was reduced to 200 μg of fluticasone plus LABA per day. Patients were randomized to 70 mg of DHEAS or placebo if their Asthma Control Questionnaire (ACQ) score was ≥2.0 and their FEV(1) ≥ 50%. When compared with control, a statistically significant improvement in ACQ in 6 weeks of treatment with 70 mg of DHEAS was observed. The median improvement in ACQ was -0.72 and -0.43 for the active and placebo groups, respectively (p = 0.0389); the percentage of patients with at least minimally clinically important difference of -0.50 from baseline was significantly greater in the DHEAS group versus the placebo, (59.4% versus 45.7%; p = 0.0236). Asthma symptom scores, the proportion of symptom-free days and symptom nights, although not statistically significant, had positive trends supporting the improvement in ACQ. Fewer patients were withdrawn from the study for respiratory events on DHEAS compared with placebo. There were few adverse events and no changes in sex hormones despite increases in circulating levels of DHEAS. An inhaled suspension of DHEAS delivered via nebulizer improved asthma control scores in subjects with poorly controlled moderate-to-severe asthma. AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY ANZCTR.ORG.AU IDENTIFIER: 012607000192482.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21708057     DOI: 10.2500/aap.2010.31.3384

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  29 in total

1.  DHEA-S inhibits human neutrophil and human airway smooth muscle migration.

Authors:  Cynthia J Koziol-White; Elena A Goncharova; Gaoyuan Cao; Martin Johnson; Vera P Krymskaya; Reynold A Panettieri
Journal:  Biochim Biophys Acta       Date:  2012-07-03

Review 2.  Dehydroepiandrosterone (DHEA): hypes and hopes.

Authors:  Krzysztof Rutkowski; Paweł Sowa; Joanna Rutkowska-Talipska; Anna Kuryliszyn-Moskal; Ryszard Rutkowski
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

3.  Androgen Receptor-Mediated Regulation of Intracellular Calcium in Human Airway Smooth Muscle Cells.

Authors:  Rama Satyanarayana Raju Kalidhindi; Rathnavali Katragadda; Kerri L Beauchamp; Christina M Pabelick; Y S Prakash; Venkatachalem Sathish
Journal:  Cell Physiol Biochem       Date:  2019

Review 4.  Novel Insights on Sex-Related Differences in Asthma.

Authors:  Peng Zhang; Joe Zein
Journal:  Curr Allergy Asthma Rep       Date:  2019-09-05       Impact factor: 4.806

5.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Testosterone Decreases House Dust Mite-Induced Type 2 and IL-17A-Mediated Airway Inflammation.

Authors:  Hubaida Fuseini; Jeffrey A Yung; Jacqueline Yvonne Cephus; Jian Zhang; Kasia Goleniewska; Vasiliy V Polosukhin; R Stokes Peebles; Dawn C Newcomb
Journal:  J Immunol       Date:  2018-08-20       Impact factor: 5.422

7.  Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age.

Authors:  W Gerald Teague; Brenda R Phillips; John V Fahy; Sally E Wenzel; Anne M Fitzpatrick; Wendy C Moore; Annette T Hastie; Eugene R Bleecker; Deborah A Meyers; Stephen P Peters; Mario Castro; Andrea M Coverstone; Leonard B Bacharier; Ngoc P Ly; Michael C Peters; Loren C Denlinger; Sima Ramratnam; Ronald L Sorkness; Benjamin M Gaston; Serpil C Erzurum; Suzy A A Comhair; Ross E Myers; Joe Zein; Mark D DeBoer; Anne-Marie Irani; Elliot Israel; Bruce Levy; Juan Carlos Cardet; Wanda Phipatanakul; Jonathan M Gaffin; Fernando Holguin; Merritt L Fajt; Shean J Aujla; David T Mauger; Nizar N Jarjour
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-31

Review 8.  Severe asthma in children.

Authors:  Theresa W Guilbert; Leonard B Bacharier; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct

9.  Elevated Testosterone Is Associated with Decreased Likelihood of Current Asthma Regardless of Sex.

Authors:  Adeeb A Bulkhi; Kirk V Shepard; Thomas B Casale; Juan Carlos Cardet
Journal:  J Allergy Clin Immunol Pract       Date:  2020-05-30

Review 10.  Hormones, sex, and asthma.

Authors:  Jeffrey A Yung; Hubaida Fuseini; Dawn C Newcomb
Journal:  Ann Allergy Asthma Immunol       Date:  2018-02-02       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.